GVHD and survival after HCT.

(A) Incidence of acute GVHD: cumulative incidence curves for patients with sustained engraftment. (B) Chronic GVHD: cumulative incidence curve for patients with sustained engraftment. Curve includes both chronic extensive and limited GVHD. (C) Survival, transplantation-related mortality, and relapse mortality after HCT. Survival estimates were 68.6% (95% CI = 54.9% to 82.2%) at 12 months and 65.0% (95% CI = 50.3% to 79.6%) at 18 months. Transplantation-related mortality (TRM) was regarded as a competing risk for death from relapse, relapse as a competing risk for TRM, and death without GVHD as a competing risk for GVHD. (D) Progression-free survival. Freedom from disease progression is shown among the entire cohort and among patients without graft rejection. Disease progression was defined as relapse from CR or disease progression that required additional chemotherapy and/or DLI after transplantation or > 25% increase in tumor measurements over those present at transplantation baseline.